CDKN2A and neoplasm: In CRC, methylated MLH1 is one of the major epigenetic biomarkers along with other genes involved in the tumor progression and metastasis, such as CDKN2A/p16(INK4A), CDKN2A/p14(ARF), MGMT, TIMP, THBS1 3, and THSD1 (thrombospondin type 1 domain containing 1), identified in genome-wide screening for methylation-silenced genes, along with meta-analysis of clinical data.